Literature DB >> 6351990

Adrenal cortical carcinoma: an unusual cause of hyperaldosteronism.

A H Telner.   

Abstract

Although secondary hyperaldosteronism due to renal vein thrombosis may occur as a result of renal cell carcinoma or adrenal cortical carcinoma, primary hyperaldosteronism is rarely associated with the latter. This paper describes a patient with adrenal cortical carcinoma who presented with the clinical features of primary hyperaldosteronism 1 year after hypertension had been diagnosed; intravenous pyelography had not been done then. Drug therapy was ineffective, and the patient died 10 weeks after presentation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6351990      PMCID: PMC1875454     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  6 in total

Review 1.  CLINICAL AND PATHOPHYSIOLOGIC ASPECTS OF ADRENOCORTICAL CARCINOMA.

Authors:  M B LIPSETT; R HERTZ; G T ROSS
Journal:  Am J Med       Date:  1963-09       Impact factor: 4.965

2.  Adrenal cortical carcinoma producing solely mineralocorticoid effect.

Authors:  L V FOYE; T V FEICHTMEIR
Journal:  Am J Med       Date:  1955-12       Impact factor: 4.965

3.  Primary aldosteronism: diagnosis, localization, and treatment.

Authors:  M H Weinberger; C E Grim; J W Hollifield; D C Kem; A Ganguly; N J Kramer; H Y Yune; H Wellman; J P Donohue
Journal:  Ann Intern Med       Date:  1979-03       Impact factor: 25.391

4.  Primary adrenocortical carcinoma causing aldosteronism.

Authors:  S L Alterman; C Dominguez; A Lopez-Gomez; A L Lieber
Journal:  Cancer       Date:  1969-09       Impact factor: 6.860

5.  Adrenal cortical carcinoma: a clinical and pathologic study of 49 cases.

Authors:  D R King; E E Lack
Journal:  Cancer       Date:  1979-07       Impact factor: 6.860

6.  Hyperaldosteronism due to unsuspected adrenal carcinoma: discovery during investigation of hypertension in a young woman.

Authors:  C E Grim; A Ganguly; M N Yum; J P Donohue; M H Weinberger
Journal:  J Urol       Date:  1981-12       Impact factor: 7.450

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.